Wednesday, September 10, 2008

Jennerex Raises $8.3M

San Francisco-based Jennerex, a biopharmaceuticals firm developing therapeutics aimed at treating cancer, said Tuesday that it has raised $8.3M in a Series B funding. Source of the funding was not disclosed. Jennerex said it would use the funding to advance its clinical development programs. The firm develops oncolytic virus therapeutics, which are currently being targeted at liver cancer, colon cancer, and lung cancer. As part of the funding, Calvin Stiller of Stilco Corporation, BioQuest Innovations, and formerly a venture capitalists at Canadian Medical Discoveries Fund, has joined the firm's board of directors. More information »